NEW YORK CITY, NY / ACCESS Newswire / April 1, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Anavex Life Sciences Corp. ("Anavex" or "the Company") (NASDAQ:AVXL). Investors who purchased Anavex securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AVXL.
Anavex Investigation Details
On March 25, 2026, Anavex issued a press release "announc[ing] that it has withdrawn its application for the marketing authorization of blarcamesine in the EU as an add-on therapy for the treatment of early Alzheimer's disease in adults, which had been under review by the European Medicines Agency (EMA)." The press release said that "[t]he decision to withdraw the application follows feedback from the EMA's Committee for Medicinal Products for Human Use (CHMP) indicating that it would not be in a position to issue a positive opinion for the application at this time." On this news, Anavex's stock price fell $1.45 per share, or 34.61%, to close at $2.74 per share on March 25, 2026.
What's Next for Anavex Investors?
If you are aware of any facts relating to this investigation or purchased Anavex securities, you can assist this investigation by visiting the firm's site: bgandg.com/AVXL. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to Anavex Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Anavex Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com
Attorney advertising.
Prior results do not guarantee similar outcomes.
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original press release on ACCESS Newswire
COMTEX_476370061/2457/2026-04-01T11:10:21